

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Severe aortic stenosis and transcatheter aortic valve replacement in elderly patients: utility vs futility

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1817691> since 2021-11-12T09:43:08Z

Published version:

DOI:10.23736/S0026-4806.21.07777-6

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

SEVERE AORTIC STENOSIS AND TRANSCATHETER AORTIC VALVE REPLACEMENT IN ELDERLY PATIENTS: UTILITY VS FUTILITY

Journal: Minerva Medica

Paper code: Minerva Med-7777

Submission date: July 28, 2021

Article type: Review Article

Files:

1. Manuscript

Version: 1

Description: manuscript

File format: application/vnd.openxmlformats-officedocument.wordprocessingml.document

SEVERE AORTIC STENOSIS AND TRANSCATHETER AORTIC VALVE REPLACEMENT IN ELDERLY PATIENTS: UTILITY VS FUTILITY

Pierfranco Terrosu* ¹, Alessandro Boccanelli ¹, Giuseppe Sabino ², Paolo Alboni ¹, Samuele Baldasseroni ¹, Mario Bo ¹, Giovambattista Desideri ¹, Niccolò Marchionni ¹, Giuseppe Palazzo ¹, Renzo Rozzini ¹, Andrea Ungar ¹, Francesco Vetta ¹, Giovanni Zito ¹

¹SICGe – Società Italiana di Cardiologia Geriatrica, Via Matteotti 7, Firenze, Italy

²UOC di Cardiologia, AOU-Ospedale SS. Annunziata, Via De Nicola 14, Sassari, Italy

*Correspondence: Pierfranco Terrosu, SICGe – Società Italiana di Cardiologia Geriatrica, Via Matteotti 7, Firenze, Italy – E-mail: pterrosu@hotmail.com

Key words: older patients, aortic stenosis, transcatheter aortic valve replacement

ABSTRACT

Introduction. Recently, transcatheter aortic valve replacement (TAVR) has emerged as established standard treatment for symptomatic severe aortic stenosis, providing an effective, less-invasive alternative to open cardiac surgery for inoperable or high-risk older patients.

Evidence acquisition. In order to assess the anticipated benefit of aortic replacement, considerable interest now lies in better identifying factors likely to predict outcome. In the elderly population frailty and medical comorbidities have been shown to significantly predict mortality, functional recovery and quality of life after transcatheter aortic valve replacement. Scientific literature focused on the three items will be discussed.

Evidence synthesis. High likelihood of futility is described in patients with severe chronic lung, kidney, liver disease and/or frailty. The addition of frailty components to conventional risk prediction has been shown to result in improved discrimination for death and

1
2
3 disability following the procedure and identifies those individuals least likely to derive benefit.

4
5 Several dedicated risk score have been proposed to provide new insights into predicted “futile”
6
7 outcome. However, assessment of frailty according to a limited number of variables is not
8
9 sufficient, while a multi-dimensional geriatric assessment significantly improves risk
10
11 prediction.
12

13
14 **Conclusions.** A multidisciplinary heart team that includes geriatricians can allow the
15
16 customization of therapeutic interventions in elderly patients to optimise care and avoid
17
18 futility.
19

20
21 **Key Words:** Transcatheter aortic valve replacement – Frailty - Older adults
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

INTRODUCTION

Transcatheter aortic valve replacement (TAVR) has emerged as a less invasive alternative to the established standard of surgical care and has offered substantial reductions in mortality and improvement in quality of life compared with medical therapy^{1,2}. Attention was initially focused on inoperable patients and those at high surgical risk^{1,3}. Thereafter, the indications have expanded for both intermediate and low-risk patients with excellent success rates and long-term outcomes^{4,5}. Although indication for TAVR has extended to also include younger groups, the majority of TAVR patients are older with significant multimorbidity. Choice of therapy in the elderly is difficult due to individual characteristics, including frailty, disability and impaired cognition⁶. As a consequence, the elderly may have suboptimal results with surgical or TAVR with higher rates of morbidity and a worse quality of life^{6,7}. Since long-term outcomes may be poorer with advancing age and with markers of advanced frailty, there remains a marked heterogeneity in outcome with up to 30% experiencing little symptomatic benefit or death within 1 year of TAVR⁶. Appropriate individual decision making in elderly care is complex and must be balanced between two opposite situations: on one hand, the less invasive nature of TAVR with its lesser morbidity is attractive; on the other hand, we often face with patients deemed as “too sick”, in which TAVR is expected to be futile.

TAVR IN ELDERLY PATIENTS: RISK PREDICTION

TAVR is now considered equivalent to conventional surgical aortic valve replacement in patients at high surgical risk and is the only options for patients with a profile of risk serious enough to be considered “inoperable”. It has become evident that chronologic age and comorbidities are insufficient to accurately predict risk and benefits of TAVR procedure and

1
2
3 that some patients do not improve functionally or live longer after TAVR. Since frailty
4
5 predisposes patients to mortality, morbidity, and poor functional recovery, assessment of
6
7 frailty has assumed a central role in the preprocedural evaluation and shared decision-making
8
9 process of potential TAVR candidates. Although the precise definition of frailty remains a
10
11 subject of debate, frailty has been usually described as a clinical multifactorial geriatric
12
13 syndrome involving multisystem impairment that results in reduced physiological reserve and
14
15 increased vulnerability to stressors. The 2017 American College of Cardiology Guidelines on
16
17 valvular heart disease⁸ highlight A) 5 min gate speed, B) disability for activities of daily living,
18
19 C) cognitive impairment, D) depression, and E) malnutrition as core indicators of frailty that
20
21 should be routinely assessed pre-TAVR.
22
23

24
25 **Frailty and general risk score.** The Society of Thoracic Surgeons (STS) score and European
26
27 System for Cardiac Operative Risk Evaluation (EuroSCORE) are developed to predict
28
29 patients' outcomes for conventional cardiac surgery procedures. However, surgical risk models
30
31 have some limitations and poorly predict TAVR outcomes^{9,10}, because they do not consider
32
33 frailty parameters. In the case of elderly patients, we must opt for a comprehensive
34
35 preoperative assessment that is not limited to surgical risk¹¹. Geriatric assessment involves an
36
37 evaluation of functional status, cognitive capacity, and social situation. In addition, the elderly
38
39 might have different goals and expectations of care than younger patient. Older frail patients
40
41 often value functional independence more than longevity¹². In contrast, current cardiac risk
42
43 stratification estimates 30-day mortality and major adverse cardiac events as primary
44
45 endpoints. Among TAVR candidates, only 7% of older patients cited survival as their main
46
47 target, while a majority of patients described a desire to perform a particular activity (48%) or
48
49 maintain independence (30%)¹³ as their primary goal. Accordingly, prediction of person-
50
51
52
53
54
55

1
2
3 centered outcomes, such as functional status, may be especially relevant to high-risk TAVR
4
5 candidates. This is why procedural outcomes should not only include clinical events but also
6
7 account for quality of life and levels of functionality. Accurately measuring TAVR outcomes
8
9 should consider integration of functional as well as frailty parameters to increase predictive
10
11 power in commonly employed risk scores. Unfortunately, commonly used surgical risk score
12
13 do not assess functional status and/or quality of life. Therefore, multidisciplinary cardiology
14
15 teams that include geriatricians has been proposed to optimize TAVR elderly patients' care.
16
17

18 **Frailty and outcome.** Frailty has proven to be associated with an increased mortality and a
19
20 higher rate of poor outcome up to 1 year after TAVR ^{14,15}. An increasing number of frailty
21
22 markers have been identified in smaller cohorts and have been associated with significantly
23
24 higher risk of adverse outcomes after TAVR ^{7,15-18}. In short, malnutrition and reduced mobility
25
26 with their counterparts ipo-albuminemia and reduced gait speed are powerful markers of frailty
27
28 status and poor outcome. Stortecky et al. showed that a comprehensive geriatric assessment of
29
30 100 consecutive TAVR patients (assessing cognition, nutrition, mobility, activities of daily
31
32 living, and frailty) significantly improved risk prediction compared with common general risk
33
34 scores ¹⁹. Moreover, Schoenenberger et al. observed an index of frailty to strongly predict post-
35
36 TAVR functional decline when adjusted for both the STS and EuroSCOREs ²⁰. However,
37
38 multiple published frailty scores show marked variability and have divergent prevalence
39
40 estimates ²¹. Wide range of frailty frequencies is observed depending on the assessment score
41
42 used (ranging between 35% and 74% in the FRAILITY-AVR study⁷). This is a major reason
43
44 why frailty is often not measured in clinical practice. Moreover, typical screening tools are
45
46 often complex and time consuming. To this regard, Afilalo et al. evaluated several frailty
47
48 scores to predict outcome after TAVR ⁷. Essential Frailty Toolset (EFT risk score including
49
50
51
52
53
54
55

1
2
3 albumin, anaemia, ability to perform chair raises and Mini-Mental State Exam) outperformed
4
5 prior described frailty scores in predicting mortality as well as worsening disability ⁷.
6
7 Accordingly, the 2019 Canadian Cardiovascular Society Position Statement for TAVR
8
9 acknowledged the EFT as a simple and predictive tool assessment tool ²². Likewise, a recent
10
11 study of Kiani et al. ²³ identified a simplified tool constituted by serum albumin, 5-min gait
12
13 speed and anaemia status. Each marker incrementally improved predictive value for poor
14
15 outcome including bleeding and readmission for heart failure. Adjusted hazard ratios for the
16
17 presence of all 3 markers was 1.4 and 2.5 for 30-days and 1-year mortality ²³. No significant
18
19 interaction was found between age and the selected frailty variables, highlighting the
20
21 relationship between frailty and outcome irrespective of age. In summary, the Kiani et al.
22
23 model ²³ represents a simple, yet powerful, algorithm and could be proposed as a useful
24
25 screening tool in clinical practice. However, although frailty indexes represent a further
26
27 important step forward in our ability to refine risk stratification and provide useful information
28
29 for shared decision making, it is unclear if treatment of these frailty markers will impact
30
31 outcomes. In practice, many frailty variables may be modifiable, since anaemia could be
32
33 corrected, hypoalbuminemia could be addressed and rehabilitation might improve mobility. It
34
35 seems reasonable to argue that improvements of frailty status may result in improvement of
36
37 symptoms. However, better understanding of how improvement of these markers will lead to
38
39 change in outcomes remains a priority to be thoroughly investigated.
40
41
42
43
44
45

46 **TAVR IN ELDERLY PATIENTS: FUTILITY**

47
48 A sizeable group of patients do not fully benefit from TAVR despite a successful procedure.
49
50 This distinction between technically “perfect” intervention and “futile” outcome ²⁴ is
51
52
53
54
55

1
2
3 important, since periprocedural results might differ much more than long-term ones. Thus,
4
5 prediction of TAVR risk can be framed in two aspects: (a) the timing of outcome (early vs.
6
7 late) and (b) the type of outcome (mortality vs. quality of life). Futility in medicine is not
8
9 uniformly defined and is under debate. From a TAVR perspective futility is usually defined
10
11 by the combination of death and/or no objective symptomatic improvement in the New York
12
13 Heart Association class. Accordingly, a poor post-TAVR outcome has been recently proposed
14
15 to include both mortality and quality-of-life measures within a single composite endpoint ²⁵.
16
17 Furthermore, definition of a futile TAVR is varying in literature on the basis of patients'
18
19 individual life goals. In clinical practice, considerable interest lies in the ability to better
20
21 identify reasons for not proceeding with TAVR ²⁶⁻²⁸. However, attention has been often
22
23 focused on comorbidities and symptoms, while objective evaluations of frailty has not been
24
25 systematically considered.
26
27

28
29 **Futility and Frailty.** Recently, a consensus paper defined subgroups of patients for which
30
31 TAVR may not be beneficial: 1) patients with life expectancy <1 year; 2) patients with
32
33 “survival with benefit” probability of <25% at 2 years. The authors described “survival with
34
35 benefit” as improvement of at least one of the followings: a) 1 class in the New-York Heart
36
37 Association function class; b) 1 Canadian Cardiovascular Society class angina symptoms; c)
38
39 improvement in the quality of life or life expectancy ²⁹. An emerging consensus incorporating
40
41 a more holistic approach suggests the importance of frailty as a factor to better identify those
42
43 patients in whom TAVR is likely to be futile ^{14-16, 30,31}. However, little is known on the impact
44
45 of frailty on quality of life after TAVR ¹⁶. A sub-study of the PARTNER Trial showed that
46
47 frailty was associated with impaired quality of life 6 months after TAVR, but this association
48
49 was not found after 12 months ¹⁶. In contrast, two other studies found that frailty at baseline is
50
51
52
53
54
55

1
2
3 an independent predictor of deterioration of quality of life 1 year after TAVR ^{32,33}. In current
4
5 literature the most commonly cited tools for frailty, namely 5-m gait speed and the Fried scale,
6
7 have shown a predictive effect on mortality, but a modest C-statistic improvement of 0.004
8
9 when added to clinical risk models ^{34,35}. These findings suggest that the assessment of a single
10
11 marker or a limited number of frailty variables may be not sufficient to achieve a reliable
12
13 prediction of long-term risk. It is reasonable to evaluate risk stratification for TAVR by
14
15 integrating markers of frailty with comorbidity and comprehensive geriatric assessment ¹¹.

16
17 **Futility and comorbidities.** Beyond frailty, current data indicate that TAVR has a high
18
19 likelihood to be futile in severe chronic lung or kidney disease, low-flow low-gradient aortic
20
21 stenosis or severe mitral regurgitation. In details, although avoiding intubation in lung disease
22
23 with transfemoral TAVR may be desirable and 50% of patients with severe COPD
24
25 demonstrated improvement of pulmonary function ³⁶, the need for oxygen supplements must
26
27 raise the discussion of futility. Chronic kidney disease is present in 30–50% of older TAVR
28
29 patients because of the inevitable decline in renal function with increasing age. However, given
30
31 the broad spectrum of chronic kidney disease, isolating the subpopulation of patients least
32
33 likely to benefit from TAVR has been challenging. It is reasonable to consider that end-stage
34
35 kidney disease and dialysis dependent patients as strong predictors of poor late survival and
36
37 futility ³⁷. In liver disease TAVR is indicated in early-stage because of its lower procedural
38
39 bleeding risk but is associated with poor late survival and high probability of futility in very
40
41 advanced liver disease ³⁸. Finally, in severe aortic stenosis lower gradients and low
42
43 transvalvular flow are usually due to left ventricular dysfunction often combined with a small
44
45 left ventricular cavity and severe mitral regurgitation ³⁹. In such patients TAVR is generally
46
47 indicated, since it might improve left ventricle function and mitral insufficiency. However, in
48
49
50
51
52
53
54
55

1
2
3 the case of severe left ventricular dysfunction without contractile reserve the results of TAVR
4
5 are poor and the probability of futility must be discussed. Recently, scientific evidence has
6
7 consistently demonstrated that aortic valve stenosis (AS) in older patients referred for TAVR
8
9 is frequently associated with cardiac amyloidosis (CA). The concurrence of AS-CA affects
10
11 around one in eight elderly patients⁴⁰, ten times higher than it is thought to be in healthy ageing
12
13 people⁴¹. AS and transthyretin CA has worse functional capacity and a trend towards worse
14
15 prognosis particularly if left untreated. Some concern has been raised about futility of TAVR
16
17 in AS-CA⁴², mostly based on limited data in small observational studies. However, the
18
19 prognostic significance of this dual diagnosis is still uncertain. Dual AS-CA pathology is
20
21 different to lone AS with the patients being slightly older and having distinct clinical risk
22
23 profiles including history of carpal tunnel syndrome, elevated biomarkers, increased septal
24
25 thickness, and right bundle-branch-block and lower voltages on ECG. Although underlying
26
27 pathophysiological aspects of AS-CA are still unclear, there are suggestions of a causal
28
29 relationship between AS and CA. In particular, the increased LV afterload posed by AS may
30
31 cause an abnormal transthyretin deposition through a mechano-enzymatic cleavage process⁴³.
32
33 Valve intervention per se could reduce mechanical stress and may actually reverse amyloid
34
35 deposition⁴³. Thus, it is not surprising that several studies have recently reported no mortality
36
37 difference between TAVR patients with and without cardiac amyloidosis⁴⁴⁻⁴⁶. Based on this
38
39 data, TAVR should therefore not be withheld in patients with AS-CA and the benefit-risk ratio
40
41 of TAVR should be evaluated by the local heart team.
42
43
44
45
46
47

48 **Futility and Risk Score.** A combined endpoint including mortality and quality-of-life
49
50
51
52
53
54
55

1
2
3 measures was applied to the PARTNER trial to identify patients at high risk for a poor outcome
4
5 post-TAVR ³¹. Baseline predictors of poor outcomes included reduced exercise capacity
6
7 (measured using 6 minutes walking test), lower baseline mean aortic valve gradients, oxygen-
8
9 dependent lung disease, chronic kidney disease and poor baseline cognition. Despite the
10
11 inclusion of two indices of functional and cognitive capacity, this model demonstrated a
12
13 limited performance, identifying only 10% of patients with a $\geq 50\%$ likelihood of a poor post-
14
15 TAVR outcome ³¹. However, several important additional factors in the multi-geriatric
16
17 assessment of patients were not considered. More recently, a new TAVR futility risk model
18
19 derived from prespecified variables of existing literature has been proposed by Zusman et al.
20
21 ⁴⁷. Final risk score included mean AV gradient, use of diuretics, baseline NYHA functional
22
23 class, haemoglobin and creatinine levels, nonfemoral access, previous oncological disease, and
24
25 previous implantation of permanent pacemaker. The model's performance was fairly good,
26
27 producing a risk of futility of 7%, 17% and 49% respectively for low, moderate and high-risk
28
29 subgroups. This risk model on the validation cohort (AUC 0.70) outperformed STS (AUC
30
31 0.60), Euroscore2 (AUC 0.55), TVT score (AUC 0.56), and TAVR 2-score (0.53) ($p = .03$ for
32
33 difference in AUC) ⁴⁷. The authors concluded that the prediction score may help to identify
34
35 patients at risk of futility, having a risk of death that may outweigh the potential benefit
36
37 anticipated with TAVR. Finally, Lantelme et al. developed a Futile TAVR Simple score (FTS)
38
39 validated for 1-year all-cause deaths after TAVR (considered as futility) ⁴⁸. The final logistic
40
41 regression model included older age, simple clinical variables and markers of depression and
42
43 denutrition. The FTS score (AUC 0.674) outperformed EuroSCORE II (AUC 0.627), Charlson
44
45 comorbidity index (AUC 0.562), and frailty index (AUC 0.486) for identifying futility ⁴⁸.
46
47 Moreover, using 3 risk categories the FTS showed a good performance to predict futility in
48
49
50
51
52
53
54
55

1
2
3 high-risk group⁴⁸ (1-year death rate at 43%, which is very similar to that of severe aortic
4 stenosis medically treated). In general, TAVR-specific risk scores show significant limitations.
5
6 Firstly, quantitative rather than binary coding of comorbidities and markers of frailty might not
7 properly assess the long-term risk of TAVR. Secondly, the addition of a limited number of
8 variables leads only to a moderate improvement in the predictive value of multivariate models.
9
10 Therefore, TAVR risk score would likely be a compromise between a multidimensional
11 approach versus more isolated and simplistic tests. While expecting further data and fine-
12 tuning the definitions of futility for TAVR, we should consider the use of balloon-aortic-
13 valvuloplasty for highly symptomatic patients as a “bridge to decision” therapy.
14
15
16
17
18
19
20
21
22
23
24

25 CONCLUSION

26
27 In conclusion, current evidence suggests that older patients who undergo TAVI have similar
28 outcomes to younger patients. However, there is marked heterogeneity in outcome and a
29 considerable proportion of patients fail to obtain a functional or mortality benefit from TAVR.
30
31 General surgical scores do not take into account TAVR-specific variables and are not reliable
32 to estimate operative risk for TAVR. In older patients, frailty and co-morbidities are of great
33 importance as predictors of death and
34 disability following TAVR. In particular, TAVR has a high likelihood to be futile or result in
35 a poor outcome in patients with severe chronic lung, kidney, liver disease and/or frailty. Thus,
36 the role of frailty and comorbidity should be part of a holistic evaluation of the patient and
37 must be integrated into a clinical decision-making process. However, several reports suggest
38 that the assessment of frailty according to a limited number of variables is not sufficient, while
39 a multi-dimensional geriatric assessment significantly improved risk prediction. A
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

1
2
3 multidisciplinary cardiology team that includes geriatricians can provide appropriate selection
4
5 of elderly patients to optimise care and avoid futility.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

PEER REVIEW COPY
Minerva Medica

Bibliografia

1. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al., PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med*. 2010;363:1597–1607.
2. Reynolds MR, Magnuson EA, Lei Y, Leon MB, Smith CR, Svensson LG, et al. Placement of Aortic Transcatheter Valves (PARTNER) Investigators. Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. *Circulation*. 2011;124:1964–1972.
3. Smith CR, Leon MB, Mack MJ, et al., PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med* 2011;364:2187–98.
4. Leon MB, Smith CR, Mack MJ, et al., PARTNER 2 Investigators. Transcatheter or surgical aorticvalve replacement in intermediate-risk patients. *N Engl J Med* 2016;374:1609–20.
5. Mack MJ, Leon MB, Thourani VH, et al., PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. *N Engl J Med* 2019;380:1695–705.
6. Lindman BR, Alexander KP, O’Gara PT, et al. Futility, benefit, and transcatheter aortic valve replacement. *JACC Cardiovasc Interv* 2014;7:707–16.
7. Afilalo J, Lauck S, Kim DH, et al. Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study. *J Am Coll Cardiol* 2017;70:689-700.
8. Nishimura RA, et al. 2017 AHA/ACC focused Update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American heart association task force on clinical practice Guidelines. *Circulation* 2017;135(25):e1159–95.
9. Biancari F, Juvonen T, Onorati F, et al. Meta-analysis on the performance of the EuroSCORE II and the Society of Thoracic Surgeons Scores in patients undergoing aortic valve replacement. *J Cardiothorac Vasc Anesth* 2014;28:1533–9.
10. Martin GP, Sperrin M, Ludman PF, et al. Inadequacy of existing clinical prediction models for predicting mortality after transcatheter aortic valve implantation. *Am Heart J* 2017;184:97–105.
11. Hosler QP, Maltagliati AJ, Shi SM, Afilalo J, Popma JJ, Khabbaz KR, Laham RJ, Guibone K, Kim DH. A practical two-stage frailty assessment for older adults undergoing aortic valve replacement. *J Am Geriatr Soc*. 2019;67:2031–2037.

12. Fried TR, Tinetti ME, Iannone L, O'Leary JR, Towle V, Van Ness PH. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. *Arch Intern Med.* 2011;171:1854–6.
13. Coylewright M, Palmer R, O'Neill ES, Robb JF, Fried TR. Patient-defined goals for the treatment of severe aortic stenosis: a qualitative analysis. *Health Expect.* 2016;19:1036–43.
14. Goudzwaard JA, de Ronde-Tillmans M, El FaquirNet al. The Erasmus frailty score is associated with delirium and 1-year mortality after Transcatheter aortic valve implantation in older patients.The TAVI Care&Cure program. *Int J Cardiol* 2019;276:48–52.
15. Green P, Woglom AE, Genereux P et al. The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a single-center experience. *J Am Coll Cardiol Interv* 2012;5:974–81.
16. Green P, Arnold SV, Cohen DJ, et al. Relation of frailty to outcomes after transcatheter aortic valve replacement (from the PARTNER trial). *Am J Cardiol* 2015;116:264–9.
17. Hinterbuchner L, Strohmer B, Hammerer M, Prinz E, Hoppe UC, Scherthaner C. Frailty scoring in transcatheter aortic valve replacement patients. *Eur J Cardiovasc Nurs* 2016;15:384–97.
18. Forcillo J, Condado JF, Ko YA, et al. Assessment of commonly used frailty markers for high- and extreme-risk patients undergoing transcatheter aortic valve replacement. *Ann Thorac Surg* 2017;104:1939–46.
19. Stortecky S, Schoenenberger AW, Moser A, Kalesan B, Juni P, Carrel T, Bischoff S, Schoenenberger CM, Stuck AE, Windecker S, Wenaweser P. Evaluation of multidimensional geriatric assessment as a predictor of mortality and cardiovascular events after transcatheter aortic valve implantation. *JACC Cardiovasc Interv* 2012;5:489–496.
20. Schoenenberger AW, Stortecky S, Neumann S, Moser A, Juni P, Carrel T, Huber C, Gandon M, Bischoff S, Schoenenberger CM, Stuck AE, Windecker S, Wenaweser P. Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). *Eur Heart J* 2013;34:684–692.
21. Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. *J Am Coll Cardiol* 2014;63:747–62.
22. Asgar AW, Ouzounian M, Adams C, Afilalo J, Frenes S, Lauck S et al. 2019 Canadian cardiovascular society position statement for Transcatheter aortic valve implantation. *Can J Cardiol.* 2019;35:1437–48.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
23. Kiani S, Stebbins A, Thourani VH, et al. The effect and relationship of frailty indices on survival after transcatheter aortic valve replacement. *J Am Coll Cardiol Intv* 2020;13:219–31.
24. Zusman O, Kornowski R, Witberg G, et al. Transcatheter aortic valve implantation futility risk model development and validation among treated patients with aortic stenosis. *Am J Cardiol.* 2017;120:2241-2246.
25. Arnold SV, Spertus JA, Lei Y, Green P, Kirtane AJ, Kapadia S, Thourani VH, Herrmann HC, Beohar N, Zajarias A, Mack MJ, Leon MB, Cohen DJ. How to define a poor outcome after transcatheter aortic valve replacement: conceptual framework and empirical observations from the placement of aortic transcatheter valve (PARTNER) trial. *Circ Cardiovasc Qual Outcomes* 2013;6:591–597.
26. Bach DS, et al. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement. *Circulation.* 2009;2:533–9.
27. Badran A, Vohra H, Livesey S. Unoperated severe aortic stenosis: decision making in an adult UK-based population. *Ann R Coll Surg Engl.* 2012;94:416–21.
28. Everett RJ, Clavel M-A, Pibarot P, Dweck MR. Timing of intervention in aortic stenosis: a review of current and future strategies. *Heart.* 2018;104:2067–76.
29. Mack MJ, Leon MB, Smith CR et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. *The Lancet* 2015; 385: 2477–84.
30. Otto CM, Kumbhani DJ, Alexander KP, Calhoun JH, Desai MY, Kaul S, et al. 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology Task Force on clinical expert consensus documents. *J Am Coll Cardiol.* 2017;69(10):1313–46.
31. Arnold SV, Reynolds MR, Lei Y et al. Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (placement of aortic Transcatheter valve) trial. *Circulation* 2014; 129: 2682–90.
32. Biermann J, Horack M, Kahlert P et al. The impact of transcatheter aortic valve implantation on quality of life: results from the German transcatheter aortic valve interventions registry. *Clin Res Cardiol* 2015;104: 877–86.
33. Goudzwaard JA, de Ronde-Tillmans M, van Hoorn F, Kwekkeboom E, Lenzen MJ, vanWiechen M et al. Impact of frailty on health-related quality of life 1 year after transcatheter aortic valve implantation. *Age and Ageing* 2020;49:989-994

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
34. Afilalo J, Kim S, O'Brien S, et al. Gait speed and operative mortality in older adults following cardiac surgery. *JAMA Cardiol* 2016;1:314–21.
 35. Alfredsson J, Stebbins A, Brennan JM, et al. Gait speed predicts 30-day mortality after transcatheter aortic valve replacement: results from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. *Circulation* 2016;133:1351–9.
 36. Gilmore RC, Thourani VH, Jensen HA, Condado J, Binongo JN, Sarin EL, et al. Transcatheter aortic valve replacement results in improvement of pulmonary function in patients with severe aortic stenosis. *Ann Thorac Surg.* 2015;100(6):2167–73.
 37. Conrotto F, Salizzoni S, Andreis A, et al. Transcatheter aortic valve implantation in patients with advanced chronic kidney disease. *Am J Cardiol* 2017;119:1438-42.
 38. Tirado-Conte G, Rodes-Cabau J, Rodriguez-Olivares R, et al. Clinical outcomes and prognosis markers of patients with liver disease undergoing transcatheter aortic valve replacement: a propensity score-matched analysis. *Circ Cardiovasc Interv* 2018;11:e005727.
 39. Fanaroff AC, Manandhar P, Holmes DR, et al. Peripheral artery disease and transcatheter aortic valve replacement outcomes: a report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Therapy Registry. *Circ Cardiovasc Interv* 2017;10:e005456.
 40. Nitsche N, Scully PR, Patel KP, Kammerlander A, Koschutnik M, Dona C et al. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. *J Am Coll Cardiol.* 2020 [Epub ahead of print]
 41. Longhi S, Guidalotti PL, Quarta CC et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. *JACC Cardiovasc imaging* 2014;7:531-2.
 42. Ternacle J, Krapf L, Mohty D et al. Aortic Stenosis and Cardiac Amyloidosis: JACC Review Topic of the Week. *J Am Coll Cardiol* 2019;74:2638-2651
 43. Marcoux J, Mangione PP, Porcari R et al. A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. *EMBO molecular medicine* 2015;7:1337-49.
 44. Nitsche C, Aschauer S, Kammerlander AA et al. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. *Eur J Heart Fail* 2020;22:1852-1862

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
45. Scully PR, Patel KP, Treibel TA et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. *Eur Heart J* 2020;41:2759–2767
 46. Rosenblum H, Masri A, Narotsky DL et al. Unveiling Outcomes in Coexisting Severe Aortic Stenosis and Transthyretin Cardiac Amyloidosis. *Eur J Heart Fail* 2020 [Epub ahead of print]
 47. Zusman O, Barbash MI, Guetta V, Finkelstein A, Assali A, Segev A et al. Predicting the risk of late futile outcome after transcatheter aortic valve implantation. *Catheter Cardiovasc Interv.* 2020;96:E695-E702.
 48. Lantelme P, Lacour T, Bisson A, Herbert J, Ivanes F, Bourguignon T et al. Futility Risk Model for Predicting Outcome After Transcatheter Aortic Valve Implantation. *Am J Cardiol* 2020;130:100-110.

Authors' contribution:

All authors read and approved the final version of the manuscript